Natera reports stronger-than-expected Q2 revenue growth and raises long-term guidance amid rising demand for diagnostic testing.
Natera posted Q2 revenue of $752.75M, up 37.7% year-over-year and $91.46M above estimates. The company’s GAAP EPS of -$0.47 also exceeded expectations by $0.04.
Revenue growth was driven by higher diagnostic testing volumes, outpacing the prior quarter’s $547.8M and consensus estimates near $661.3M. The company raised its 2026 revenue outlook to a range of $2.85 billion to $2.91 billion, up from previous guidance.
Natera now expects 2026 gross margins of 64% to 66%, reflecting improved operational efficiency. The updated guidance signals confidence in sustained demand for its genetic testing services.